Drug Prices | Association for Accessible Medicines
THANK YOU - for all those who made our first-ever #GRxBiosims virtual conference a success.

Drug Prices

2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report

In 2019, the U.S. health care system saved $313 billion in 2019 from generics and biosimilar drugs, including $96 billion in Medicare savings and $48.5 billion in savings to Medicaid. At a time when access to reliable, affordable and high-quality prescription medication is more important than ever, generics fill 90% of prescriptions in the United States for only 20% of the cost.

How to Talk About High Drug Costs in a Time of Economic Insecurity

A Reference Guide for Lawmakers

Health care and the cost of prescription drugs are top issues for voters across the country. AAM developed a resource for effective communications around the concern for the rising cost of prescription drugs during COVID-19, “How to Talk About High Drug Costs in a Time of Economic Insecurity." This primer outlines how anticompetitive tactics limit patient access to FDA-approved generics and biosimilars, and how competition helps reduce drug prices.

AAM Supports Updating Medicare to Lower Costs for America’s Seniors

Even though generics and biosimilars provide consistent savings for taxpayers and consumers, today’s Medicare patients too often face obstacles to using these lower-cost options. This is a result of outdated policies that can unintentionally encourage plans to prioritize formulary placement of high-cost brand drugs and that fail to reflect the emergence of new competitive therapies.

The First (Price) Cut Is the Steepest

Congress Must Preserve the 180-Day Incentive for First Generics

In the debate over how to lower the cost of prescription drugs, one thing is certain: Generic competition drives savings for America’s patients and our health care system. The introduction of generic medicines offers patients the same high-quality medicine as the brand-name drug, but at an average price that is 39% lower according to the U.S.

White Paper: Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution

Generic medicines are an integral component of America’s pharmaceutical care system, driving substantial savings to patients and public programs. Even as spending on prescription drugs continues to rise in public programs, the use of generic medicines has blunted increasing brand drug prices, generating savings of $293 billion in 2018 alone. In fact, the average price of generic drugs covered under Medicare Part D in 2017 was only 26% of their average price in 2006.

Give IPR the Green Light

Congress created Inter Partes Review (IPR) to improve patent quality and expedite access to safe and affordable generic and biosimilar medicines. IPR is a process that allows patent experts to take a second look at patents and ensure that every granted patent represents true innovation. This graphic demonstrates how IPR improves patent quality, accelerates competition and makes lower-cost generics and biosimilars accessible to U.S. patients. Learn more in this infographic:

Subscribe to Drug Prices

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.